Evaluation of Platelet Elevation after Injection in Patients Over 40 Years of Age Admitted Hospital; A Retrospective Study

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Anesthesiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Anesthesiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Hemostasis is a hemodynamic process in which the platelet and vessel wall play a major role. Platelet therapy is a standard care for patients with thrombocytopenia. However, some studies reported a progressive decline in platelet elevation after 1, 18, and 24 hours.Methods: In this retrospective study, 35 cases of patients over 40 years of age undergoing platelet injections were enrolled. Blood platelet levels were measured before and after platelet transfusion, and platelet elevation levels were determined according to patients' demographic and clinical variables.Findings: The average platelet count after platelet injection was significantly higher than the mean before it (P < 0.001). Factors such as gender, splenomegaly, fever, and heparin had significant effect on the changes in platelet count (P < 0.050); but the bleeding factor has no significant effect on it.Conclusion: The incidence of thrombocytopenia and death in patients admitted to intensive care unit is high and should be worrying. Our results indicate that platelet injection is effective in patients requiring it, and may increase platelet levels in these patients after injection. In addition, several factors, such as sex, splenomegaly, fever, and heparin affect platelet levels after injection.

Keywords

References

  1. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med 1976; 295(5): 237-41.
  2. Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91(9): 3509-17.
  3. Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71(2): 383-7.
  4. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86(9): 3598-603.
  5. Estcourt LJ. Why has demand for platelet components increased? A review. Transfus Med 2014; 24(5): 260-8.
  6. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103(2): 390-8.
  7. Brand A. Alloimmune platelet refractoriness: incidence declines, unsolved problems persist. Transfusion 2001; 41(6): 724-6.
  8. Guidelines for transfusion for massive blood loss. A publication of the British Society for Haematology. British Committee for Standardization in Haematology Blood Transfusion Task Force. Clin Lab Haematol 1988; 10(3): 265-73.
  9. Cimo PL, Moake JL, Weinger RS, Ben-Menachem YB, Khalil KG. Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol 1979; 6(2): 125-33.
  10. Crookston KP, Reiner AP, Cooper LJ, Sacher RA, Blajchman MA, Heddle NM. RBC T activation and hemolysis: implications for pediatric transfusion management. Transfusion 2000; 40(7): 801-12.
  11. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994; 66(3): 200-5.
  12. Pirzadeh A, Forouzanfar M, Asdaghi Z. Assessment of therapeutic platelet transfusion effectiveness in thrombocytopenic hospitalized patients in hematology unit of Emam Khomeini Hospital, Ardabil [MD Thesis]. Ardabil: Ardabil University of Medical Sciences; 2012. [In Persian].
  13. Arnold DM, Crowther MA, Cook RJ, Sigouin C, Heddle NM, Molnar L, et al. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion 2006; 46(8): 1286-91.
  14. Menitove JE, Aster RH. Transfusion of platelets and plasma products. Clin Haematol 1983; 12(1): 239-66.
  15. Hester JP, McCredie KB, Fneineich EI. Platelet replacement therapy: A clinical assessment. In: Greenwalt TJ, Jamieson GA, editors. The blood platelet in transfusion therapy. New York, NY: A. R. Liss; 1978. p. 281.
  16. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993; 81(12): 3428-34.
Journal of Isfahan Medical School
Volume 35, Issue 451 - Serial Number 451
September and October 2017
Pages 1438-1443

Files

History

  • Receive Date: 04 September 2017
  • Revise Date: 06 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics